← Back to dossier
Patient handout

Upper-extremity DVT (subclavian / axillary / brachial)

PRODUCTION

1. Your condition

This handout is for upper-extremity dvt (subclavian / axillary / brachial). Your care team identified this based on: unilateral arm swelling, pain, warmth, prominent collateral veins → suggests uedvt.

Other reasons your team may use this plan: young athlete with repetitive arm overhead activity (rowing, swimming, weightlifting) → paget-schroetter (primary uedvt); cvc, picc, port, or pacemaker lead present → secondary uedvt (most common cause).

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

MedicationStarting doseHowWhenWhat it does
apixaban10 mg BID × 7 d → 5 mg BIDPOBID × ≥3 months (or while catheter in place)AMPLIFY PMID 23808982 — UEDVT extrapolated; ACCP 2021 supports DOAC for UEDVT
rivaroxaban15 mg BID × 21 d → 20 mg dailyPOBID then daily × ≥3 monthsEINSTEIN-DVT subgroup; ACCP 2021
edoxaban60 mg daily after 5 d LMWH lead-inPOdaily × ≥3 monthsHokusai-VTE PMID 23991958 — UEDVT included in trial
enoxaparin1 mg/kg SC BIDSCBIDASH 2018 in pregnancy; CARAVAGGIO PMID 32223112 alt in cancer-UEDVT
alteplase0.5-1 mg/h via catheter for 12-24 hIV_cathetercontinuous infusionCDT for primary (Paget-Schroetter) within 14 d restores venous patency; Engelberger Thromb Res 2014; Joffe ASH 2017

Plan: Upper-extremity DVT anticoagulation — DOAC-first per ACCP 2021

3. When to call your provider

Contact your care team if any of the following happen:

  • Recurrent UEDVT → re-evaluate anatomy and AC strategy

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

  • UEDVT extending to or causing SVC syndrome (facial swelling, plethora, dyspnea, dilated chest collaterals)(life-threatening)
  • Massive UEDVT with brachial plexus compression causing new motor or sensory deficit
  • UEDVT with concurrent PE (~10-15% rate) — particularly common in catheter-associated UEDVT(life-threatening)

5. Follow-up

Primary: surgical (thoracic surgery / vascular) consult for first-rib resection within 4-6 weeks. Secondary: AC continued while catheter in place (or 3 months if removed)

6. Sources

Guideline: ACCP/CHEST 2021 Antithrombotic + ASH 2020 VTE Treatment + Joffe ASH 2017 UEDVT review

  1. pubmed.ncbi.nlm.nih.gov/34352295
  2. pubmed.ncbi.nlm.nih.gov/33007077
  3. pubmed.ncbi.nlm.nih.gov/23808982